Transgenic Leishmania and the immune response to infection

Parasite Immunology

Volumn 30, Issue 4, 2008, Pages 255-266

  Beattie, L ^a   Evans, K J ^a   Kaye, P M ^a   Smith, D F ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Imaging; Immune responses; Leishmania; Transgenesis

Indexed keywords

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; BIOLUMINESCENCE; CELL INTERACTION; DOWN REGULATION; GENE CASSETTE; GENE EXPRESSION; GENETIC PARAMETERS; GENETIC TRANSFECTION; HOST PARASITE INTERACTION; IMAGING; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; INNATE IMMUNITY; LEISHMANIASIS; MARKER GENE; NONHUMAN; PARASITE DEVELOPMENT; PARASITE VIRULENCE; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; TRANSGENIC LEISHMANIA; TRANSGENIC ORGANISM; VACCINATION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; HOST-PARASITE INTERACTIONS; HUMANS; LEISHMANIA; LEISHMANIASIS;

EID: 40449134820     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2008.01020.x     Document Type: Review

References (103)

1. Desjeux P. Leishmaniasis. Nat Rev Microbiol 2004 2 : 692.
2. Murray HW, Berman JD, Davies CR Saravia NG. Advances in leishmaniasis. Lancet 2005 366 : 1561 1577.
3. Lipoldova M Demant P. Genetic susceptibility to infectious disease: lessons from mouse models of leishmaniasis. Nat Rev Genet 2006 7 : 294 305.
4. Sacks D Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002 2 : 845 858.
5. Kaye PM, Svensson M, Ato M, et al. The immunopathology of experimental visceral leishmaniasis. Immunol Rev 2004 201 : 239 253.
6. Cruz A Beverley SM. Gene replacement in parasitic protozoa. Nature 1990 348 : 171 173.
7. Beverley SM. Protozomics: trypanosomatid parasite genetics comes of age. Nat Rev Genet 2003 4 : 11 19.
8. Naderer T, Vince JE McConville MJ. Surface determinants of Leishmania parasites and their role in infectivity in the mammalian host. Curr Mol Med 2004 4 : 649 665.
9. Mosser DM Brittingham A. Leishmania, macrophages and complement: a tale of subversion and exploitation. Parasitology 1997 115 : S9 S23.
10. Turco SJ. The leishmanial lipophosphoglycan: a multifunctional molecule. Exp Parasitol 1990 70 : 241 245.
11. Ilg T. Proteophosphoglycans of Leishmania. Parasitol Today 2000 16 : 489 497.
12. Sacks D Kamhawi S. Molecular aspects of parasite-vector and vector-host interactions in leishmaniasis. Annu Rev Microbiol 2001 55 : 453 483.
13. Descoteaux A Turco SJ. Functional aspects of the Leishmania donovani lipophosphoglycan during macrophage infection. Microbes Infect 2002 4 : 975 981.
14. Lodge R Descoteaux A. Modulation of phagolysosome biogenesis by the lipophosphoglycan of Leishmania. Clin Immunol 2005 114 : 256 265.
15. Beverley SM Turco SJ. Lipophosphoglycan (LPG) and the identification of virulence genes in the protozoan parasite Leishmania. Trends Microbiol 1998 6 : 35 40.
16. Spath GF, Epstein L, Leader B, et al. Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite Leishmania major. Proc Natl Acad Sci USA 2000 97 : 9258 9263.
17. Ilg T. Lipophosphoglycan is not required for infection of macrophages or mice by Leishmania mexicana. Embo J 2000 19 : 1953 1962.
18. Capul AA, Hickerson S, Barron T, Turco SJ Beverley SM. Comparisons of mutants lacking the Golgi UDP-Galactose or GDP-Mannose transporters establish that phosphoglycans are important for promastigote but not amastigote virulence in Leishmania major. Infect Immun 2007.
19. Garami A Ilg T. The role of phosphomannose isomerase in Leishmania mexicana glycoconjugate synthesis and virulence. J Biol Chem 2001 276 : 6566 6575. Epub 2000 November 6517.
20. Zufferey R, Allen S, Barron T, et al. Ether phospholipids and glycosylinositolphospholipids are not required for amastigote virulence or for inhibition of macrophage activation by Leishmania major. J Biol Chem 2003 278 : 44708 44718. Epub 42003 August 44727.
21. Mottram JC, Souza AE, Hutchison JE, Carter R, Frame MJ Coombs GH. Evidence from disruption of the lmcpb gene array of Leishmania mexicana that cysteine proteinases are virulence factors. Proc Natl Acad Sci U S A 1996 93 : 6008 6013.
22. Denise H, McNeil K, Brooks DR, Alexander J, Coombs GH Mottram JC. Expression of multiple CPB genes encoding cysteine proteases is required for Leishmania mexicana virulence in vivo. Infect Immun 2003 71 : 3190 3195.
23. Joshi PB, Kelly BL, Kamhawi S, Sacks DL McMaster WR. Targeted gene deletion in Leishmania major identifies leishmanolysin (GP63) as a virulence factor. Mol Biochem Parasitol 2002 120 : 33 40.
24. Peacock CS, Seeger K, Harris D, et al. Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nat Genet 2007 39 : 839 847.
25. Zhang WW Matlashewski G. Loss of virulence in Leishmania donovani deficient in an amastigote-specific protein, A2. Proc Natl Acad Sci U S A 1997 94 : 8807 8811.
26. Zhang WW Matlashewski G. Characterization of the A2-A2rel gene cluster in Leishmania donovani: involvement of A2 in visceralization during infection. Mol Microbiol 2001 39 : 935 948.
27. Zhang WW, Mendez S, Ghosh A, et al. Comparison of the A2 gene locus in Leishmania donovani and Leishmania major and its control over cutaneous infection. J Biol Chem 2003 278 : 35508 35515.
28. Tabbara KS, Peters NC, Afrin F, et al. Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection. Infect Immun 2005 73 : 4714 4722.
29. Selvapandiyan A, Duncan R, Debrabant A, et al. Genetically modified live attenuated parasites as vaccines for leishmaniasis. Indian J Med Res 2006 123 : 455 466.
30. Spath GF, Garraway LA, Turco SJ Beverley SM. The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts. Proc Natl Acad Sci USA 2003 100 : 9536 9541. Epub 2003 July 9517.
31. Uzonna JE, Spath GF, Beverley SM Scott P. Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J Immunol 2004 172 : 3793 3797.
32. Kebaier C, Uzonna JE, Beverley SM Scott P. Immunization with persistent attenuated Delta lpg2 Leishmania major parasites requires adjuvant to provide protective immunity in C57BL/6 mice. Infect Immun 2006 74 : 777 780.
33. Titus RG, Gueiros-Filho FJ, de Freitas LA Beverley SM. Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci U S A 1995 92 : 10267 10271.
34. Streit JA, Recker TJ, Filho FG, Beverley SM Wilson ME. Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms. J Immunol 2001 166 : 1921 1929.
35. Kelly BL, Stetson DB Locksley RM. Leishmania major LACK antigen is required for efficient vertebrate parasitization. J Exp Med 2003 198 : 1689 1698.
36. Kelly BL Locksley RM. The Leishmania major LACK antigen with an immunodominant epitope at amino acids 156-173 is not required for early Th2 development in BALB/c mice. Infect Immun 2004 72 : 6924 6931.
37. Saravia NG, Escorcia B, Osorio Y, et al. Pathogenicity and protective immunogenicity of cysteine proteinase-deficient mutants of Leishmania mexicana in non-murine models. Vaccine 2006 24 : 4247 4259.
38. Papadopoulou B, Roy G, Breton M, et al. Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination. Infect Immun 2002 70 : 62 68.
39. Selvapandiyan A, Debrabant A, Duncan R, et al. Centrin gene disruption impairs stage-specific basal body duplication and cell cycle progression in Leishmania. J Biol Chem 2004 279 : 25703 25710.
40. Aga E, Katschinski DM, van Zandbergen G, et al. Inhibition of the spontaneous apoptosis of neutrophil granulocytes by the intracellular parasite Leishmania major. J Immunol 2002 169 : 898 905.
41. Gueirard P, Laplante A, Rondeau C, Milon G Desjardins M. Trafficking of Leishmania donovani promastigotes in non-lytic compartments in neutrophils enables the subsequent transfer of parasites to macrophages. Cell Microbiol 2007.
42. Duclos S, Diez R, Garin J, et al. Rab5 regulates the kiss and run fusion between phagosomes and endosomes and the acquisition of phagosome leishmanicidal properties in RAW 264.7 macrophages. J Cell Sci 2000 113 Part 19 : 3531 3541.
43. Lang T, Ave P, Huerre M, Milon G Antoine JC. Macrophage subsets harbouring Leishmania donovani in spleens of infected BALB/c mice: localization and characterization. Cell Microbiol 2000 2 : 415 430.
44. Misslitz AC, Bonhagen K, Harbecke D, Lippuner C, Kamradt T Aebischer T. Two waves of antigen-containing dendritic cells in vivo in experimental Leishmania major infection. Eur J Immunol 2004 34 : 715 725.
45. Nossal GJ, Abbot A Mitchell J. Antigens in immunity. XIV. Electron microscopic radioautographic studies of antigen capture in the lymph node medulla. J Exp Med 1968 127 : 263 276.
46. Aebischer T, Bennett CL, Pelizzola M, et al. A critical role for lipophosphoglycan in proinflammatory responses of dendritic cells to Leishmania mexicana. Eur J Immunol 2005 35 : 476 486.
47. Lopez JA, LeBowitz JH, Beverley SM, Rammensee HG Overath P. Leishmania mexicana promastigotes induce cytotoxic T lymphocytes in vivo that do not recognize infected macrophages. Eur J Immunol 1993 23 : 217 223.
48. + dendritic cells in cross-presentation is not dictated by antigen capture. Proc Natl Acad Sci USA 2006 103 : 10729 10734.
49. Burgdorf S, Lukacs-Kornek V Kurts C. The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation. J Immunol 2006 176 : 6770 6776.
50. Garcia MR, Graham S, Harris RA, Beverley SM Kaye PM. Epitope cleavage by Leishmania endopeptidase (s) limits the efficiency of the exogenous pathway of major histocompatibility complex class I-associated antigen presentation. Eur J Immunol 1997 27 : 1005 1013.
51. + T cells requires the presence of cognate antigen. Infect Immun 2006 74 : 773 776.
52. + T cell recognition. Eur J Immunol 1993 23 : 2311 2319.
53. Wick MJ, Pfeifer JD, Findlay KA, Harding CV Normark SJ. Compartmentalization of defined epitopes expressed in Escherichia coli has only a minor influence on efficiency of phagocytic processing for presentation by class I and class II major histocompatibility complex molecules to T cells. Infect Immun 1993 61 : 4848 4856.
54. Wolfram M, Ilg T, Mottram JC Overath P. Antigen presentation by Leishmania mexicana-infected macrophages: activation of helper T cells specific for amastigote cysteine proteinases requires intracellular killing of the parasites. Eur J Immunol 1995 25 : 1094 1100.
55. Wolfram M, Fuchs M, Wiese M, Stierhof YD Overath P. Antigen presentation by Leishmania mexicana-infected macrophages: activation of helper T cells by a model parasite antigen secreted into the parasitophorous vacuole or expressed on the amastigote surface. Eur J Immunol 1996 26 : 3153 3162.
56. Prickett S, Gray PM, Colpitts SL, Scott P, Kaye PM Smith DF. In vivo recognition of ovalbumin expressed by transgenic Leishmania is determined by its subcellular localization. J Immunol 2006 176 : 4826 4833.
57. Shen H, Miller JF, Fan X, Kolwyck D, Ahmed R Harty JT. Compartmentalization of bacterial antigens: differential effects on priming of CD8 T cells and protective immunity. Cell 1998 92 : 535 545.
58. + T cells by Leishmania major-infected dendritic cells. Infect Immun 2005 73 : 6620 6628.
59. Bertholet S, Goldszmid R, Morrot A, et al. Leishmania antigens are presented to CD8+ T cells by a transporter associated with antigen processing-independent pathway. In Vitro Vivo J Immunol 2006 177 : 3525 3533.
60. Tobin JF, Reiner SL, Hatam F, et al. Transfected Leishmania expressing biologically active IFN-γ. J Immunol 1993 150 : 5059 5069.
61. Field AE, Wagage S, Conrad SM Mosser DM. Reduced pathology following infection with transgenic Leishmania major expressing murine CD40 ligand. Infect Immun 2007 75 : 3140 3149.
62. Conrad SM, Strauss-Ayali D, Field AE, Mack M Mosser DM. Leishmania-derived murine monocyte chemoattractant protein 1 enhances the recruitment of a restrictive population of CC chemokine receptor 2-positive macrophages. Infect Immun 2007 75 : 653 665.
63. Cameron P, McGachy A, Anderson M, et al. Inhibition of lipopolysaccharide-induced macrophage IL-12 production by Leishmania mexicana amastigotes: the role of cysteine peptidases and the NF-κB signaling pathway. J Immunol 2004 173 : 3297 3304.
64. Hutchens M Luker GD. Applications of bioluminescence imaging to the study of infectious diseases. Cell Microbiol 2007.
65. Roy G, Dumas C, Sereno D, et al. Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models. Mol Biochem Parasitol 2000 110 : 195 206.
66. Lang T, Goyard S, Lebastard M Milon G. Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice. Cell Microbiol 2005 7 : 383 392.
67. Cahalan MD Parker I. Imaging the choreography of lymphocyte trafficking and the immune response. Curr Opin Immunol 2006 18 : 476 482.
68. Gray PM, Reiner SL, Smith DF, Kaye PM Scott P. Antigen-experienced T cells limit the priming of naive T cells during infection with Leishmania major. J Immunol 2006 177 : 925 933.
69. Denny PW, Gokool S, Russell DG, Field MC Smith DF. Acylation-dependent protein export in Leishmania. J Biol Chem 2000 275 : 11017 11025.
70. Burchmore RJ, Rodriguez-Contreras D, McBride K, et al. Genetic characterization of glucose transporter function in Leishmania mexicana. Proc Natl Acad Sci USA 2003 100 : 3901 3906. Epub 2003 March 3921.
71. Dubessay P, Blaineau C, Bastien P, et al. Cell cycle-dependent expression regulation by the proteasome pathway and characterization of the nuclear targeting signal of a Leishmania major Kin-13 kinesin. Mol Microbiol 2006 59 : 1162 1174.
72. Wirtz E Clayton C. Inducible gene expression in trypanosomes mediated by a prokaryotic repressor. Science 1995 268 : 1179 1183.
73. Sheader K, Vaughan S, Minchin J, Hughes K, Gull K Rudenko G. Variant surface glycoprotein RNA interference triggers a precytokinesis cell cycle arrest in African trypanosomes. Proc Natl Acad Sci USA 2005 102 : 8716 8721. Epub 2005 June 8713.
74. Yan S, Myler PJ Stuart K. Tetracycline regulated gene expression in Leishmania donovani. Mol Biochem Parasitol 2001 112 : 61 69.
75. Yan S, Martinez-Calvillo S, Schnaufer A, Sunkin S, Myler PJ Stuart K. A low-background inducible promoter system in Leishmania donovani. Mol Biochem Parasitol 2002 119 : 217 223.
76. Smith DF, Peacock CS Cruz AK. Comparative genomics: from genotype to disease phenotype in the leishmaniases. Int J Parasitol 2007 37 : 1173 1186. Epub 2007 June 1123.
77. Cruz A, Coburn CM Beverley SM. Double targeted gene replacement for creating null mutants. Proc Natl Acad Sci USA 1991 88 : 7170 7174.
78. Monte-Alegre A, Ouaissi A Sereno D. Leishmania amastigotes as targets for drug screening. Kinetoplastid Biol Dis 2006 5 : 6.
79. Ryan KA, Dasgupta S Beverley SM. Shuttle cosmid vectors for the trypanosomatid parasite Leishmania. Gene 1993 131 : 145 150.
80. Gay LS, Wilson ME Donelson JE. The promoter for the ribosomal RNA genes of Leishmania chagasi. Mol Biochem Parasitol 1996 77 : 193 200.
81. Ryan KA, Garraway LA, Descoteaux A, Turco SJ Beverley SM. Isolation of virulence genes directing surface glycosyl-phosphatidylinositol synthesis by functional complementation of Leishmania. Proc Natl Acad Sci USA 1993 90 : 8609 8613.
82. Huang C Turco SJ. Defective galactofuranose addition in lipophosphoglycan biosynthesis in a mutant of Leishmania donovani. J Biol Chem 1993 268 : 24060 24066.
83. Davoudi N, Tate CA, Warburton C, Murray A, Mahboudi F McMaster WR. Development of a recombinant Leishmania major strain sensitive to ganciclovir and 5-fluorocytosine for use as a live vaccine challenge in clinical trials. Vaccine 2005 23 : 1170 1177.
84. Sereno D, Roy G, Lemesre JL, Papadopoulou B Ouellette M. DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening. Antimicrob Agents Chemother 2001 45 : 1168 1173.
85. Singh N Dube A. Short report: fluorescent Leishmania: application to anti-leishmanial drug testing. Am J Trop Med Hyg 2004 71 : 400 402.
86. Ashutosh Gupta S, Ramesh Sundar S Goyal N. Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening. Antimicrob Agents Chemother 2005 49 : 3776 3783.
87. Kamau SW, Grimm F Hehl AB. Expression of green fluorescent protein as a marker for effects of antileishmanial compounds in vitro. Antimicrob Agents Chemother 2001 45 : 3654 3656.
88. Bart G, Frame MJ, Carter R, Coombs GH Mottram JC. Cathepsin B-like cysteine proteinase-deficient mutants of Leishmania mexicana. Mol Biochem Parasitol 1997 88 : 53 61.
89. Alexander J, Coombs GH Mottram JC. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J Immunol 1998 161 : 6794 6801.
90. Joshi PB, Sacks DL, Modi G McMaster WR. Targeted gene deletion of Leishmania major genes encoding developmental stage-specific leishmanolysin (GP63). Mol Microbiol 1998 27 : 519 530.
91. Soleimani M, Mahboudi F, Davoudi N, et al. Expression of human tissue-type plasminogen activator (t-PA) in Leishmania tarentolae. Biotechnol Appl Biochem 2007.
92. Morales MA, Renaud O, Faigle W, Shorte SL Spath GF. Over-expression of Leishmania major MAP kinases reveals stage-specific induction of phosphotransferase activity. Int J Parasitol 2007.
93. Belen Carrillo M, Gao W, Herrera M, et al. Heterologous expression of Trypanosoma cruzi trans-sialidase in Leishmania major enhances virulence. Infect Immun 2000 68 : 2728 2734.
94. Lodge R, Diallo TO Descoteaux A. Leishmania donovani lipophosphoglycan blocks NADPH oxidase assembly at the phagosome membrane. Cell Microbiol 2006 8 : 1922 1931. Epub 2006 July 1911.
95. Winberg ME, Rasmusson B Sundqvist T. Leishmania donovani: inhibition of phagosomal maturation is rescued by nitric oxide in macrophages. Exp Parasitol 2007 14 : 14.
96. Ilg T, Demar M Harbecke D. Phosphoglycan repeat-deficient Leishmania mexicana parasites remain infectious to macrophages and mice. J Biol Chem 2001 276 : 4988 4997.
97. Garami A Ilg T. Disruption of mannose activation in Leishmania mexicana: GDP-mannose pyrophosphorylase is required for virulence, but not for viability. Embo J 2001 20 : 3657 3666.
98. Spath GF, Lye LF, Segawa H, Turco SJ Beverley SM. Identification of a compensatory mutant (lpg2-REV) of Leishmania major able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strategies. Infect Immun 2004 72 : 3622 3627.
99. Selvapandiyan A, Duncan R, Debrabant A, et al. Expression of a mutant form of Leishmania donovani centrin reduces the growth of the parasite. J Biol Chem 2001 276 : 43253 43261.
100. Misslitz A, Mottram JC, Overath P Aebischer T. Targeted integration into a rRNA locus results in uniform and high level expression of transgenes in Leishmania amastigotes. Mol Biochem Parasitol 2000 107 : 251 261.
101. Dumas C, Muyombwe A, Roy G, et al. Recombinant Leishmania major secreting biologically active granulocyte-macrophage colony-stimulating factor survives poorly in macrophages in vitro and delays disease development in mice. Infect Immun 2003 71 : 6499 6509.
102. Buxbaum LU, Denise H, Coombs GH, Alexander J, Mottram JC Scott P. Cysteine protease B of Leishmania mexicana inhibits host Th1 responses and protective immunity. J Immunol 2003 171 : 3711 3717.
103. Dyall SD, Denny PW, Seepersaud R, McGhie D Smith DF. Expression of the AM gene locus in infective stages of Leishmania. Mol Biochem Parasitol 2000 109 : 73 79.